(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 February 2011 (17.02.2011)

PCT

(10) International Publication Number
WO 2011/018225 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *A61K 31/70* (2006.01)
C07K 16/28 (2006.01) *A61K 31/137* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/EP2010/004940

(22) International Filing Date:
12 August 2010 (12.08.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09010488.6 14 August 2009 (14.08.2009) EP
10162391.6 10 May 2010 (10.05.2010) EP

(71) Applicant *(for all designated States except US)*: **ROCHE GLYCART AG** [CH/CH]; Wagistrasse 18, CH-8952 Schlieren (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DREYLING, Martin** [DE/DE]; Zweigstr. 8, 82152 Planegg (DE). **HEINRICH, Daniel, Alexander** [DE/DE]; Bauerstr. 21, 80796 Muenchen (DE). **HERTING, Frank** [DE/DE]; An der Freiheit 29a, 82377 Penzberg (DE). **KLEIN, Christian** [DE/CH]; Chruezacherweg 41, CH-8906 Bonstetten (CH).

(74) Agent: **BURGER, Alexander**; Roche Diagnostics GmbH, Patent Department (TR-E), Postfach 11 52, 82372 Penzberg (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*


Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONE

Fig. 1



(57) Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone.

WO 2011/018225 A1